- Home
- NUW vs MNPR Comparison
NUW vs MNPR Comparison
Compare NUW & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- MNPR
- Stock Information
- Founded
- NUW 2008
- MNPR 2014
- Country
- NUW United States
- MNPR United States
- Employees
- NUW N/A
- MNPR N/A
- Industry
- NUW Investment Managers
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- NUW Finance
- MNPR Health Care
- Exchange
- NUW Nasdaq
- MNPR Nasdaq
- Market Cap
- NUW 246.8M
- MNPR 209.3M
- IPO Year
- NUW N/A
- MNPR 2019
- Fundamental
- Price
- NUW $13.57
- MNPR $44.97
- Analyst Decision
- NUW
- MNPR Strong Buy
- Analyst Count
- NUW 0
- MNPR 7
- Target Price
- NUW N/A
- MNPR $62.00
- AVG Volume (30 Days)
- NUW 45.3K
- MNPR 69.2K
- Earning Date
- NUW 01-01-0001
- MNPR 08-08-2025
- Dividend Yield
- NUW 3.66%
- MNPR N/A
- EPS Growth
- NUW N/A
- MNPR N/A
- EPS
- NUW N/A
- MNPR N/A
- Revenue
- NUW N/A
- MNPR N/A
- Revenue This Year
- NUW N/A
- MNPR N/A
- Revenue Next Year
- NUW N/A
- MNPR N/A
- P/E Ratio
- NUW N/A
- MNPR N/A
- Revenue Growth
- NUW N/A
- MNPR N/A
- 52 Week Low
- NUW $12.45
- MNPR $1.72
- 52 Week High
- NUW $14.44
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- NUW 42.82
- MNPR 59.21
- Support Level
- NUW $13.51
- MNPR $44.26
- Resistance Level
- NUW $13.63
- MNPR $47.52
- Average True Range (ATR)
- NUW 0.08
- MNPR 3.49
- MACD
- NUW -0.02
- MNPR 0.54
- Stochastic Oscillator
- NUW 16.24
- MNPR 64.49
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.